What is the 13F Pro Quality Score for LH?

13F Pro ranks LABCORP HOLDINGS INC. (LH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LH's current score at https://13fpro.ai/research/LH (free sign-up required for the full ranking).

Where does 13F Pro source LH data?

All LABCORP HOLDINGS INC. fundamentals and ownership data come directly from SEC EDGAR. LABCORP HOLDINGS INC. files with the SEC under CIK 920148. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LH in?

LABCORP HOLDINGS INC. (LH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LH research updated on 13F Pro?

LH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LABCORP HOLDINGS INC.(LH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 920148 LH stock profile & AI dashboard →

13F Pro Quality Score

54.8/100

Rank #1,196 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

16.6/100

Profitability

62.2/100

Balance Sheet

71.9/100

Earnings Quality

37.7/100

Free Cash Flow

52.5/100

Institutional Flow

40.9/100

Revenue Scale

89.8/100

Dilution Risk

59.9/100

LH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for LABCORP HOLDINGS INC. (LH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LH at 54.8/100 on a 32-signal composite quality model, placing it at rank #1,196 of 2,879 stocks — the top half of the AI-ranked universe. LH scores in the top quartile across revenue scale (89.8). Areas of concern include revenue growth (16.6) and earnings quality (37.7), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), LABCORP HOLDINGS INC. reports quarterly revenue of $3.5B, net income of $277.8M, an operating margin of 10.8%. Top institutional holders of LH by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, VICTORY CAPITAL MANAGEMENT, based on the most recent SEC filings. LH trades on the NYSE exchange and files with the SEC under CIK 920148. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LABCORP HOLDINGS INC. directly from SEC EDGAR. LABCORP HOLDINGS INC.'s 13F Pro composite quality score has ranged between 8 and 65 since 2024, currently 54.8 — an improving long-term trajectory across 44 quarterly and live scoring snapshots.

✦

Fun facts about LABCORP HOLDINGS INC.

Quirks, history, and lore behind LH — the kind of stuff that makes a stock memorable.

1
The Basics
A U.S. healthcare company · large-cap · listed on the NYSE · headquartered in North Carolina.
2
The Numbers
Annual revenue of roughly $15 billion, processing hundreds of millions of tests each year — one of the highest-volume lab operations on the planet.
3
The History
Born from a 1995 merger of two rival clinical lab networks, it grew through decades of acquisitions into a near-duopoly alongside one well-known competitor.
4
The Secret
It's not just blood draws — the company also runs one of the largest drug development and clinical trial testing businesses in the world.
5
The Lore
During the COVID-19 pandemic, it became a household name by processing millions of coronavirus tests, suddenly famous for something most people never thought about before.
6
The Giveaway
You've almost certainly had your blood work sent here — they operate thousands of patient service centers nationwide under a name that rhymes with 'lab corp.'

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$3.5B

Net Income

Q1 2026

$277.8M

Free Cash Flow

Q1 2026

$70.5M

Operating Margin

Q1 2026

10.8%

ROIC

Q1 2026

2.6%

D/E Ratio

Q1 2026

0.73

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+7.2% YoY

$13.95BFY 2025

FY22 $11.86BFY23 $12.16BFY24 $13.01BFY25 $13.95B

Net Income

+17.5% YoY

$876.5MFY 2025

FY22 $1.28BFY23 $418.0MFY24 $746.0MFY25 $876.5M

Operating Income

+27.4% YoY

$1.38BFY 2025

FY22 $1.44BFY23 $725.6MFY24 $1.09BFY25 $1.38B

EPS (Diluted)

+18.3% YoY

$10.46FY 2025

FY22 $13.97FY23 $4.77FY24 $8.84FY25 $10.46

Total Assets

+0.1% YoY

$18.39BFY 2025

FY22 $20.16BFY23 $16.73BFY24 $18.38BFY25 $18.39B

Total Debt

-23.8% YoY

$5.58BFY 2025

FY22 $5.34BFY23 $5.05BFY24 $7.33BFY25 $5.58B

Op. Cash Flow

+3.4% YoY

$1.64BFY 2025

FY22 $1.96BFY23 $1.33BFY24 $1.59BFY25 $1.64B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$13.95B +7.2%	$13.01B +7.0%	$12.16B +2.5%	$11.86B -9.7%	$13.14B -6.0%	$13.98B
Net Income	$876.5M +17.5%	$746.0M +78.5%	$418.0M -67.3%	$1.28B -46.2%	$2.38B +52.8%	$1.56B
Operating Income	$1.38B +27.4%	$1.09B +49.8%	$725.6M -49.5%	$1.44B -52.9%	$3.05B +24.7%	$2.45B
EPS (Diluted)	$10.46 +18.3%	$8.84 +85.3%	$4.77 -65.9%	$13.97 -42.7%	$24.39 +53.6%	$15.88
Total Assets	$18.39B +0.1%	$18.38B +9.9%	$16.73B -17.0%	$20.16B -1.1%	$20.39B +1.6%	$20.07B
Total Debt	$5.58B -23.8%	$7.33B +45.1%	$5.05B -5.3%	$5.34B -1.4%	$5.42B -6.5%	$5.80B
Operating Cash Flow	$1.64B +3.4%	$1.59B +19.4%	$1.33B -32.1%	$1.96B -37.1%	$3.11B +45.6%	$2.14B

AI Insight: LH Ratio Trends

LabCorp's operating margin recovered to 10.8% in Q1 2026 after plunging to 7.6% in Q4 2025, but exhibits high quarterly volatility.

• Operating margin swung from 11.2% in Q2 2025 to 7.6% in Q4 2025, then rebounded to 10.8% in Q1 2026.

• ROE improved from 7.6% in Q4 2025 to 12.7% in Q1 2026, reaching the highest level in the data set.

• Debt-to-equity ratio increased from 0.58 in Q3 2025 to 0.73 in Q1 2026.

⚠ Profitability metrics show extreme quarterly swings, with Q4 consistently weaker than other quarters.

⚠ ROIC declined from peak of 11.7% in Q2 2025 to 10.1% in Q1 2026 despite margin recovery.

Get alerted when LH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LABCORP HOLDINGS INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LH

BlackRock, Inc.
$1.7B6,444,856 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.4B5,376,120 sh
VICTORY CAPITAL MANAGEMENT INC
$1.2B4,627,126 sh
STATE STREET CORP
$1.0B3,863,171 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$982.0M3,680,661 sh
Boston Partners
$632.4M2,368,796 sh
Allspring Global Investments Holdings, LLC
$607.2M2,226,446 sh
GEODE CAPITAL MANAGEMENT, LLC
$581.0M2,185,942 sh
Select Equity Group, L.P.
$580.3M2,174,785 sh
MORGAN STANLEY
$399.7M1,498,027 sh

Fund	Value	Shares
BlackRock, Inc.	$1.7B	6,444,856
VANGUARD CAPITAL MANAGEMENT LLC	$1.4B	5,376,120
VICTORY CAPITAL MANAGEMENT INC	$1.2B	4,627,126
STATE STREET CORP	$1.0B	3,863,171
VANGUARD PORTFOLIO MANAGEMENT LLC	$982.0M	3,680,661
Boston Partners	$632.4M	2,368,796
Allspring Global Investments Holdings, LLC	$607.2M	2,226,446
GEODE CAPITAL MANAGEMENT, LLC	$581.0M	2,185,942
Select Equity Group, L.P.	$580.3M	2,174,785
MORGAN STANLEY	$399.7M	1,498,027

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LH on your watchlist

Track score changes the day LABCORP HOLDINGS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LH a good stock to buy?

13F Pro's AI-powered analysis of LABCORP HOLDINGS INC. (LH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LH are available on the LH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LABCORP HOLDINGS INC.'s investment landscape.